
==== Front
Curr Atheroscler Rep
Curr Atheroscler Rep
Current Atherosclerosis Reports
1523-3804
1534-6242
Springer US New York

39133247
1229
10.1007/s11883-024-01229-z
Review
Targeting Macrophage Phenotypes and Metabolism as Novel Therapeutic Approaches in Atherosclerosis and Related Cardiovascular Diseases
Wang Juan wangjuan.goal@163.com

1
Wu Qiang 23
Wang Xinyu 1
Liu Hongbin 4
Chen Mulei 1
Xu Li 1
Zhang Ze 5
Li Kuibao 1
Li Weiming liweiming@sina.com

1
Zhong Jiuchang jczhong@sina.com

1
1 grid.24696.3f 0000 0004 0369 153X Beijing Key Laboratory of Hypertension, Heart Center of Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2 https://ror.org/04gw3ra78 grid.414252.4 0000 0004 1761 8894 Senior Department of Cardiology, the Sixth Medical Center, Chinese PLA General Hospital, Beijing, China
3 https://ror.org/04gw3ra78 grid.414252.4 0000 0004 1761 8894 Journal of Geriatric Cardiology Editorial Office, Chinese PLA General Hospital, Beijing, China
4 https://ror.org/04gw3ra78 grid.414252.4 0000 0004 1761 8894 Department of Cardiology, the Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
5 https://ror.org/00wksha49 grid.410717.4 0000 0004 0644 5086 National Institute of Biological Sciences, Beijing, China
12 8 2024
12 8 2024
2024
26 10 573588
22 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Purpose of the review

Macrophage accumulation and activation function as hallmarks of atherosclerosis and have complex and intricate dynamics throughout all components and stages of atherosclerotic plaques. In this review, we focus on the regulatory roles and underlying mechanisms of macrophage phenotypes and metabolism in atherosclerosis. We highlight the diverse range of macrophage phenotypes present in atherosclerosis and their potential roles in progression and regression of atherosclerotic plaque. Furthermore, we discuss the challenges and opportunities in developing therapeutic strategies for preventing and treating atherosclerotic cardiovascular disease.

Recent findings

Dysregulation of macrophage polarization between the proinflammatory M1 and anti-inflammatory M2 phenotypealters the immuno-inflammatory response during atherosclerosis progression, leading to plaque initiation, growth, and ultimately rupture. Altered metabolism of macrophage is a key feature for their function and the subsequent progression of atherosclerotic cardiovascular disease. The immunometabolism of macrophage has been implicated to macrophage activation and metabolic rewiring of macrophages within atherosclerotic lesions, thereby shifting altered macrophage immune-effector and tissue-reparative function.

Summary, Insights and Perspective

Targeting macrophage phenotypes and metabolism are potential therapeutic strategies in the prevention and treatment of atherosclerosis and atherosclerotic cardiovascular diseases. Understanding the precise function and metabolism of specific macrophage subsets and their contributions to the composition and growth of atherosclerotic plaques could reveal novel strategies to delay or halt development of atherosclerotic cardiovascular diseases and their associated pathophysiological consequences. Identifying biological stimuli capable of modulating macrophage phenotypes and metabolism may lead to the development of innovative therapeutic approaches for treating patients with atherosclerosis and coronary artery diseases.

Graphical Abstract

Keywords

Atherosclerosis
Macrophage
Phenotype
Metabolism
Coronary artery diseases
J.W. National Natural Science Fund81900382 Wang Juan J.W. Beijing Municipal Natural Science Foundation, 72220727222072 Wang Juan JC.Z. National Natural Science Fund92168117 92168117 Chen Mulei Zhong Jiuchang JC.Z. Beijing Municipal Natural Science Foundation7222068 Zhong Jiuchang issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Atherosclerosis is a metabolic and inflammatory disease characterized by the accumulation of cholesterol-rich lipoproteins and inflammatory cells in the arterial wall, which primarily occurs in regions with disturbed laminar flow [1]. The build-up of lipoproteins containing apolipoprotein B is the initiating step. Atherosclerosis is the leading cause of cardiovascular events such as myocardial infarctions and strokes, resulting in 17.9 million deaths annually around the world [1]. Over the last two decades, macrophages have been identified as significant pathological features in the progression of atherosclerosis and thrombotic complications. Monocytes differentiate into macrophages at these sites, engulfing the accumulated lipoproteins. While initially beneficial, this process ultimately leads to the formation of foam cells laden with cholesterol contributing to plaque formation. The subsequent progression of plaques depends on a continuous influx of monocytes from the bloodstream, which fuels the accumulation of macrophages within the plaque. Moreover, Under the stimulation of pathological conditions such as hypertension, macrophages secret various cytokines to promote the formation and progression of atherosclerosis [2]. Precise regulation of macrophage activation is crucial for controlling atherosclerosis and maintenance the stability of plaques. Macrophages play a dual role as sources of inflammation and regulators of homeostasis, adapting to the complex and dynamic metabolism changes at different stages of atherosclerotic plaque progression. Importantly, metabolic pathways not only provide energy but also influence the macrophage polarization and function. In this article, we focus on the regulatory roles and underlying mechanisms of macrophage phenotypes, metabolism and activation in atherosclerosis and discuss the potential of targeting macrophages for therapeutic intervention in atherosclerosis and atherosclerotic cardiovascular diseases (ASCVD).

Origins of Lesion Macrophages

Macrophages widely distributes throughout nearly every tissue of our bodies and play a crucial role in the innate immune system. It is now known that macrophages have diverse and context-specific functions in various physiological and pathophysiological contexts [3]. During the progression of atherosclerosis, under the influence of proinflammatory stimuli, hematopoietic stem and progenitor cells originating from the bone marrow migrate to the spleen, where they differentiate into monocytes. These splenic monocytes are subsequently released into the blood circulation and then recruited to organs with inflammation, such as the atherosclerotic artery wall [4]. The process of monocyte extravasation commences with rolling along the endothelium mediated by P- and E-selectin, followed by firm adhesion mediated by intercellular cell adhesion molecules (ICAM), vascular cell adhesion molecules (VCAM), and integrins [5]. Subsequent transendothelial migration requires interaction between C–C motif chemokine receptor (CCR) 2 and monocyte chemoattractant protein 1/ chemokine (C–C motif) ligand 2 (MCP1/CCL2) as well as the involvement of CCR5 and CX3C chemokine receptor (CX3CR) 1. Deficiency or reduction of these receptors has been linked to a significant decrease of atherosclerosis. Monocytes penetrate the arterial vessel wall through the extensive network of highly permeable neovascularization developing during progression of plaque [6]. Within the intima, bone marrow derived-monocytes differentiate into macrophages under the simulation of M-CSF or GM-CSF. These macrophages proliferate and sustain the sterile inflammation. The macrophages in the mouse aorta wall during atherogenesis are derived from circulating monocytes and local proliferation, leading to 20-fold increase in macrophage numbers [7]. Before reaching the artery wall, monocytes are exposed to various pathophysiological stimuli in the systemic context. Evidence from studies of monocytes isolated from patients as well as mouse models of atherosclerosis indicates that this exposure modulates both cellular metabolism and function, promotes monocytes polarized to an inflammatory phenotype well before their differentiation within the atherosclerotic microenvironment. Among the various monocyte subpopulations in circulation, the CD14+ subpopulation in humans and the Ly6Chi subpopulation in mice, are significantly associated with macrophage differentiation in the progression of atherosclerosis [8].

Macrophages Polarization is Depending on Stimuli and Activated Signaling Pathways

Macrophages play a crucial role in innate immunity by expressing multiple pattern recognition receptors, including Toll-like receptors (TLRs), Ig superfamily (FcR), GPI-anchored (CD14), scavenger (CD36) and lectin like receptors (Dectin-1) (Table 1), which are strategically located in the macrophage cell membrane, cytoplasm, and endosomal compartment [9]. Traditionally, macrophage activation and metabolism have been implicated in two main subtypes: M1 macrophages, induced by various stimuli such as tumor necrosis factor α (TNFα), IFN­γ, lipopolysaccharides (LPS), TLRs, pathogen-associated molecular complexes, lipoproteins as well as M2 macrophages, alternatively activated by IL-4 and IL­13 stimulation. However, it is now understood that these macrophage phenotypes represent extremes and serve as starting point for understanding macrophage activation and metabolism in atherosclerosis (Fig. 1). Macrophages have diverse functions including maintaining of tissue homeostasis, inducing and resolving immune responses during pathogen infection and participating in tissue repair [10, 11]. Upon sensing various stimuli, macrophages become activated and polarized to different cellular states. For example, microbial stimuli activate M1 macrophages, which secrete pro-inflammatory factors such as IL-1β, IL-6, TNF-α, IL-12, IL-23, nitric oxide (NO), and reactive oxygen species (ROS), contributing to tissue destruction [12–14]. M1-like macrophages express inducible nitric oxide synthase (iNOS), TLR2, TLR4, CD68, CD80, and CD86, along with pro-inflammatory transcription factors like nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription (STAT)-1. They play a predominant role in pathogen defense, phagocytosis, destruction of foreign bodies, as well as antigen presentation to T cells, triggering an adaptive immune response [15, 16]. In terms of metabolism, M1 macrophages exhibit increased aerobic glycolysis and decreased oxidative phosphorylation (OXPHOS). They kill intracellular pathogens and prime their polarization to this phenotype in atherosclerosis. M1 macrophages generated reactive oxygen and nitrogen species to eliminate bacterial, fungal, and viral infections, which may worsen oxidative stress in the plaque [17]. Additionally, M1 macrophages express different chemokine (C-X-C motif) receptor ligands such as CXCL9, CXCL10, and CXCL5, which recruit Th1 and natural killer cells to eradicate intracellular pathogens [18]. While these functions are beneficial in acute infection, they can cause tissue damage and impair wound healing in sterile inflammation generated within atherosclerosis [19].Table 1 Macrophage receptors in immune recognition

Receptor family	Example	Function	
Nuclear receptors	PPARγ, ERRα, LXRα	A sensor of fatty acids, apoptotic cell and phagocytosis	
Scavenger	SR-A, CD36	Phagocytosis of bacteria and apoptotic cells, endocytosis of modified LDL	
GPI-anchored	CD14	LPS-binding protein/interactions, TLR signaling, apoptotic cell recognition	
TAM receptors	Tyro3, Axl, MerTK	Promote apoptotic cell clearance	
Integrin	CR3 (CD18/11b)	Complement receptor mediated phagocytosis, adhesion to endothelium	
Ig superfamily	FcR (ITAM/ITIM)	Antibody-dependent binding, uptake, killing	
Seven transmembrane	CCR2

C5aR

P2Y receptors

	Regulation of inflammation, receptor for MCP-1, chemotaxis, degranulation, myeloid cell adhesion, chondroitin sulphate binding	
NK-like C-type lectin-like	Dectin-1

(ITAM-like)

	β -glucan receptor, fungal, particle ingestion

TNF-α release/interaction TLR2

	
C-type lectin	DC-SIGN, MR	Enhance uptake of Dengue virus and human immunodeficiency, pathogen recognition, clearance, alternative activation	
NOD-like receptors	NOD1, NLRP3	Macrophage activation and maturation of dendritic cells to drive antigen-specific adaptive immune responses	
Toll-like receptors

(Leucine-rich repeats)

	TLR2, TLR4	Response to peptidoglycan, response to LPS	
PPARγ: peroxisome proliferator-activated receptor γ, ERRα: estrogen related receptor α, LXRα: Liver X receptors α, SR-A: scavenger receptor, CCR2: chemokine receptor 2, C5aR: C5a receptor, DC-SIGN: DC-specific intercellular adhesion molecule-grabbing nonintegrin, MR: mannose receptor (CD206), NOD1: nucleotide-binding oligomerization domain, TLR: toll-like receptor

Fig. 1 Phenotypes and metabolic mechanism of macrophages in the progression of atherosclerotic plaque and related cardiovascular diseases. Macrophages with different functional phenotypes are likely to perform different roles in the development of atherosclerosis. Macrophages in early atherosclerotic lesions are predominantly derived from monocytes recruited from the blood cycle. Monocyte adhesion to endothelial cells and migration into the arterial vessel wall, whereas macrophage proliferation and local inflammation are the primary features. With the progression of atherosclerosis, macrophage engulf lipoprotein-derived cholesterol, leading to foam cell formation, macrophage apoptosis, the plaque lesions towards to a vulnerable type known as unstable atherosclerotic plaques with large necrotic cores and thin fibrous caps. Unstable plaques are prone to rupture, which may cause thrombus formation and arterial occlusion contributing to myocardial infarction and sudden cardiac death

In the context of worm and parasite infection, macrophages are activated into an alternative state known as M2 macrophages, which play an active role in tissue repair and remodeling [20]. M2 macrophages have been categorized into four distinct subtypes: M2a, M2b, M2c and M2d macrophages. M2a macrophages are stimulated by IL-4 and IL-13 and express high levels of the mannose receptors [21, 22]. These macrophages secrete pro-fibrotic factors such as fibronectin, insulin-like growth factor (IGF), and transforming growth factor β (TGF-β), contributing to tissue repair [23, 24]. On the other hand, M2b macrophages are activated by immune complexes, such as TLR ligands, IL-1 receptor agonists and they produce both anti-inflammatory (IL-10) and pro-inflammatory (IL-1, IL-6, TNFα) cytokines along with TGF-β1 [25]. Furthermore, M2c macrophages are induced by IL-10 and glucocorticoids, while M2d macrophages are activated by IL-6 and express inflammatory cytokines (TGF- β, VEGF and IL-10) [26]. Traditionally, M2a macrophages are known as “wound healing macrophages”, whereas M2b and M2c macrophages are referred as “regulatory macrophages” [27]. They are characterized by the expression of arginase 1 (Arg1), mannose receptor C type 1 (CD206), chitinase-like protein 3 (Chil3), Chil4, and found in inflammatory zone-1 (Fizz1). The expression of Arg1 and Fizz1 depends on signal transducer and STAT6 signaling [28]. M2 macrophages also secrete multiple chemokines such as CCL17, CCL18, CCL22, and CCL24. They exhibit anti-inflammatory cytokine profile with low production of IL-12 and high production of IL-10or TGF-β [29]. Furthermore, M2 macrophages prevent cholesterol from accumulation due to increased expression of cholesterol efflux receptors, especially adenosine triphosphate (ATP)-binding cassette transporters (ABC), ABCA1 and ABCG1. Certain subsets of heme-dependent macrophages are associated with efficient phagocytosis of red cells [30]. However, due to the overlapping expression of certain markers among different subtypes of M2 macrophages, their phenotypic differentiation can be challenging. Therefore, it is crucial to categorize macrophage phenotypes based on surface marker expression and their specific functions. Nevertheless, the phenotypic spectrum of macrophages in vivo may be more complex than this classification suggests. However, how this subclassification of M2 macrophages mentioned above corresponds to their specific roles in atherosclerosis remains largely unclear. Apart from the classical subsets, there are other phenotypes. Mox macrophages are induced by oxidized LDL (oxLDL) and promote atherogenesis. M4 macrophages are induced by platelet chemokine CXCL4 and can be identified by the absence of the hemoglobin–haptoglobin scavenger receptor CD163, while they express a combination of CD68, S100A8 and MMP7. Similar to M1 macrophages, M4 macrophages exhibit proinflammatory characteristics, but lack phagocytotic capacity. Moreover, vulnerable plaques can develop intraplaque hemorrhage (IPH), leading to the release of free hemoglobin (Hb) and subsequent uptake haptoglobin binding to the CD163 receptor, which triggers differentiation into M (Hb) or Mhem macrophage. M (Hb) macrophages. Compared to foam cells, M (Hb) macrophage lacks lipid accumulation and exhibit high surface expression of CD163 and CD206 (Table 2), located in areas of angiogenesis and hemorrhage, produce both anti-inflammatory (IL-10, IL-1ra) and pro-inflammatory (IL-6, IL-1β) factors.Table 2 Macrophage subtypes in animal and humans

Phenotype	Species	Polarized by	Markers	Function	
M1	Human	Mice	IFN-γ, TNF α, LPS	TNFα, IL-6, IL-1β CXCL10, CXCL11, CXCL16, CCL5, Arg-2 (mouse), iNOS, ROS	Pro-inflammatory response	
M2	M2a	Human	Mice	IL-4, IL-13 and M-CSF	CD206, Arg1, Ym1, FIZZ1, IL-10, TGF-β	Anti-inflammatory and wound healing	
M2b	Human	Mice	TLR ligands, IL-1R agonist	CD206, IL-1 β, IL-6, TNF-α, IL-12, IL-10	Immuno-regulation and promoting infections	
M2c	Human	Mice	IL-10, Glucocorticoids, TGF-β	CD206, CD163, MerTK, IL-10, TGF- β	Efferocytosis and tissue remodeling	
M2d	Mice	TLR and adenosine A2A receptor ligands, IL-6	VEGF, IL-10, TGF- β

IL-12, TNF-α (Low)

	Angiogenesis, resistant to lipid accumulation	
M4	Human	CXCL4	IL-6, TNF-α	Reduced phagocytosis, proinflammatory	
M(Hb)	Human	Hemoglobin	CD68, HMOX-1, sulfiredoxin-1,	Iron-handling capacities,

anti-inflammatory

	
Mhem	Human	Mice	Heme	CD68, CD163	HMOX-1	
Mox	Mice	Oxidized phospholipids	CD68, CD163, CD206	Antioxidant	
CXCL: (C–X–C motif) ligand, CCL: chemoattractant chemokines ligand, iNOS: inducible nitric oxide synthase, ROS: reactive oxygen species, M-CSF: macrophage colony-stimulating factor, VEGF: vascular endothelial growth factor, TGF-β, transforming growth factor β, FIZZ1: found in inflammatory zone 1, HMOX-1: heme oxygenase-1

M1-like macrophages are predominantly associated with inflammatory processes and often observed in unstable plaques, while M2-like macrophages are predominantly present in stable plaques and the adventitia of arteries [31]. We hypothesize that the phenotype of lesional macrophages cannot be neatly classified into predefined subsets but rather emerges as a result of the lesional microenvironment and the activation of specific signaling pathways. For example, the activation of TLR4 triggers the activation of NF-κB, ERK, p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and interferon response genes, thereby leading to different downstream effects. Conversely, stimulation of IL-4 receptor triggers the activation of signal transducer and STAT6, which can suppress TLR4 signaling [32]. Notably, STAT6 shifts macrophages from an inflammatory M1-like phenotype to a more stable M2-like phenotype [33]. Consequently, the phenotype of lesional macrophages rapidly changes in response to alterations of the microenvironment and intracellular signaling pathways. Metabolic pathways play a crucial role in immune cell function. In vitro studies have revealed significant metabolic difference between M1 and M2 macrophages.M2 macrophages more rely on fatty acid oxidation (FAO), whereas M1 macrophages mainly rely on an increase in glycolysis [34–36]. Additionally, IL − 4 and IL − 10 enhance lipid uptake of macrophages and promote foam cell formation, while inflammatory M1 and Mox macrophages display lower foam cell activity. Functionally, there are key differences between the M1 and Mox macrophages phenotypes that account for the balance of foam cell formation. M1 exhibit reduced lipid uptake, whereas Mox macrophages compensate for this by increasing lipid efflux activity [37]. Increased glycolysis just through overexpression of the glucose transporter 1 (GLUT1) in myeloid cells is insufficient to promote inflammatory activation in atherosclerosis [38]. However, inhibiting glycolysis in activated macrophages can lead to increased apoptosis, potentially contributing to the formation of necrotic cores. The microenvironment within lesions is likely to vary across different regions and stages of the lesion development and is affected by systemic factors dyslipidemia, inflammation associated with diabetes mellitus, autoimmune disease and infection. Therefore, we propose that immunometabolism would change with macrophage metabolic pathways and play important role in cell phenotypes and function. The interconnected pathways of glycolysis, tricarboxylic acid (TCA) cycle, the pentose-phosphate pathway (PPP), FAO, and amino acid metabolism contribute to generation of energy required for cellular maintenance, proliferation and modulation of cellular signaling [35]. Thus, we provide a brief overview of these highly interdependent metabolic contributors to macrophage phenotype: glucose, lipid and amino acid metabolism and how they are interconnected and intersect in macrophage activation and effector function (Fig. 2, Table 3).Fig. 2 Schematic representation of macrophage immunometabolism pathways. (A) LPS/IFN-γ induced macrophage. The enhanced glycolysis and pentose phosphate pathway, generating NADPH for reactive oxygen species, nitric oxide and a disturbed TCA cycle. (B) IL-4 induced macrophage. An intact TCA cycle resulting in sustained ATP production via oxidative phosphorylation (OXPHOS). ROS, reactive oxygen species; NO, nitric oxide; OXPHOS: oxidative phosphorylation; PPP: pentose phosphate pathway; IL4, interlukin-4; FAO: fatty acid oxidation; TCA, tricarboxylic acid

Table 3 Six major metabolic pathways in macrophage subsets

	M1	M2	
Glycolysis	Glycolysis is a key feature of M1 macrophages	Crucial in sustained IL-4-induced macrophage activation	
OXPHOS	Impaired OXPHOS via the TCA cycle	The main metabolic characteristics of M2 macrophages	
PPP	Generating the required redox power by the formation of NADPH, in order to sustain macrophage functions such as ROS handling and anti-oxidative protection	Generate NADPH, ROS handling and anti-oxidative protection	
FAO	FAO promote activation of NLRP3 and secretion of proinflammatory cytokine IL-1 β	FAO yields a number of products including acetyl-CoA, NADH is linked to the M2 state and regulate tissue repair	
Cholesterol metabolism	Cholesterol crystals promote nuclear translocation of PKM2 to drive metabolic reprogramming and M1 macrophage polarization	HDL attenuates macrophage necroptosis by activating Akt signaling in macrophages in an SR-B1 and PDZK1-dependent manner and attenuate the development of necrotic cores	
Amino acid metabolism	Glutamine is important for the induction of IL-1 by macrophages in response to LPS stimulation	Arginine support macrophage proliferation and collagen production used in tissue repair	
OXPHOS: oxidative phosphorylation, TCA: tricarboxylic acid, NADPH: nicotinamide adenine dinucleotide phosphate, PPP: pentose phosphate pathway, FAO: fatty acid oxidation

Mechanism of Glycolysis in Macrophage during Atherosclerosis

The conventional perspective widely acknowledges that glycolysis is a prominent characteristic of M1 macrophages [39], while FAO and OXPHOS are the main metabolic characteristics of M2 macrophages. Although substantial efforts have been made to unravel the mechanisms linking metabolic reprogramming and macrophage function, numerous questions remained. Glycolysis drives inflammatory macrophage responses in different ways. The utilization of glucose through glycolysis generates ATP as a form of energy and crucial intermediates, which functions as substrates for other metabolic pathways. For example, pyruvate can be further converted to lactate or Acetyl-CoA, two major metabolites important for macrophage metabolic adaptations. In addition, the generation of serine from glycolysis to sustain cellular one-carbon metabolism may regulate epigenetic reprogramming during macrophage activation [40]. This one-carbon metabolism is essential for nucleotide synthesis and methylation reactions, influencing gene expression patterns in activated macrophages. Although glycolysis produces only a small amount of ATP (2 per glucose), it can be activated swiftly to meet immediate energy demands. On the other hand, OXPHO, induced by signals such as IL-4 in macrophages, is a slower process but produces greater amounts of ATP (30 per glucose). This metabolic shift enables M1 macrophages to rapidly respond to inflammatory stimuli, while M2 macrophages, with their reliance on OXPHOS, are better suited for long-term, energy-efficient responses involved in tissue repair and anti-inflammatory functions.

Atherosclerotic plaques often harbor regions of hypoxia where oxygen availability is limited. In response to hypoxia and pro-inflammatory factors cell regulate hypoxia-inducible factor-1 (HIF-1), triggering a cascade of metabolic adaptations. One notable effect is the increased expression of GLUT1 and the glycolytic enzyme pyruvate kinase M2 (PKM2). This contributes to enhanced glucose uptake, glycolysis, glycolytic flux as well as upregulated expression of the key glycolysis proteins GLUT1, hexokinase II (HK-II), and 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB3) [41]. In patients with coronary artery disease (CAD), elevated glycolysis drives mitochondrial ROS production and promote the expression increased levels of pro-IL-1β and inflammasome activation. It then phosphorylates and activates signal transducer and activator of transcription (STAT3), to promote the production of inflammatory cytokines like IL-1 β and IL-6 [42]. A recent study unveiled that HIF-1α in orchestrating glycolytic reprogramming through induction of pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1) and inhibition of HIF-1α-PDK1 axis promote systemic inflammation, suggesting that glycolysis contributes to macrophage migratory activity [43]. Notably, cellular response to hypoxia, including degradation of HIF proteins and HIF-dependent transcriptional programs, can occur as quickly as 24 h after exposure to hypoxia conditions [44, 45].

Contrary to conventional beliefs, recent studies have shed new light on the significance of glycolysis in M2 macrophage activation. IL-4 increased glucose metabolism through AKT and mechanistic target of rapamycin (mTOR) complex (mTORC) 1 [46]. This was evidenced by the blockage of glycolysis with 2-deoxyglucose (2-DG) strikingly which attenuated the IL-4 induced expression of Arg1, Fizz1, and CD301b, pivotal in sustaining glucose metabolism and overall energy balance [47]. Accordingly, inhibition of mitochondrial ATP synthase with oligomycin and glycolysis with 2-DG both suppress IL-4-regulated genes, surface markers and functions, implying that glucose fuels the TCA cycle for mitochondrial respiration in M2 macrophages [48, 49]. Meanwhile, recent study reassessed the role of glycolysis in M2 macrophages and found that glucose depletion, leaving OXPHOS intact, does not affect M2 activation. However, simultaneous impairment of glycolysis and OXPHOS by 2-DG resulted in reduced intracellular ATP levels and JAK-STAT6 signaling, ultimately impairing M2 differentiation. This study indicated that while glycolysis may not play a mandatory regulatory role in M2 differentiation, but it assumes an obligatory role once OXPHOS is compromised. Furthermore, suppressing both glycolysis and OXPHOS at higher doses of 2-DG led to reduced intracellular ATP content and M2 differentiation [49]. Notably, OXPHOS rather than glycolysis was the most discriminative process among macrophages in various tissues under homeostasis conditions [50]. This indicates that targeting OXPHOS may offer a more selective therapeutic approach of for macrophage-related diseases.

The Pentose Phosphate Pathway (PPP) in Macrophage

The PPP is another crucial pathway for glucose utilization in macrophage, pivotal for various cellular functions including ROS management and anti-oxidative defense by generating NADPH. While both M1 and M2 macrophages exhibit increased glycolysis, its noteworthy that only M1 macrophages activate the PPP. In M1 macrophages the PPP is bolstered by increased glucose intermediates flux and downregulation of carbohydrate kinase-like protein (CARKL) expression [39]. Conversely, M2 macrophages display decreased levels of glycolysis and PPP-associated metabolites such as lactate and sedoheptulose-7-phosphate. Macrophages rely on robust PPP flux and NADPH during respiratory bursts to combat extracellular bacteria and produce antioxidants like glutathione and thioredoxin, crucial for mitigating oxidative damage to cells. NADPH acts as a vital co-factor for lipid metabolism and other metabolic pathways, akin to ATP as a universal energy carrier utilized by diverse enzymes throughout the cellular metabolic networks. PPP activity play a vital role in redox-sensitive protein signaling during macrophage activation. Moreover, the PPP yields pentose molecules serving as precursors for nucleotide synthesis or reconvert to glycolytic intermediates [51]. Additionally, macrophages employ a noncanonical PPP loop involving repeated cycling of PPP intermediates back to glucose-6-phosphate (G6P) through a process resembling gluconeogenesis. this loop is essential for NADPH generation, ensuring appropriate phagolysosome maturation and facilitating apoptotic cell degradation [52].

The functional significance of GLUT1-mediated glucose uptake has been demonstrated through the selective ablation of GLUT1, leading to impaired glucose entry [53]. The causal relationship between hyperglycemia and atherosclerosis remains unclear. A recent study showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce blood glucose levels in diabetic mice and concomitantly prevent the stimulating effects of diabetes mellitus on myelopoiesis and the inflammatory activation of lesional macrophages [54]. These effects of are likely attribute to glucose reduction. Alternatively, it is possible that SGLT2 inhibitors exert their effects through indirect mechanisms, such as hemodynamic changes, rather than by solely preventing the direct effects of glucose on bone marrow cells or lesional cells [55]. It is crucial to determine whether monocytes, pro-inflammatory macrophages and foamy cells within the atherosclerotic plaque rely on specific and exclusive glucose dependent pathways. Furthermore, it is important to ascertain whether there is a metabolic reprogramming of macrophage glucose metabolism at a specific stage of disease progression, in a specific localization, and within a specific cell type [56].

Fatty Acid Oxidation (FAO) May Regulate Bioenergetics of Macrophage

Proinflammatory macrophages rely on glycolysis for their metabolic processes, whereas anti-inflammatory macrophages are thought to dependent on FAO. FAO occurs primarily within the mitochondrial matrix, serving as a significant ATP source, especially when glucose availability is limited. Besides bioenergetics, FAO may also generated metabolites that influence signal transduction and gene regulation [57]. IL-4 signaling activates the transcription factor STAT6, leading to increased expression of genes regulating FAO and mitochondrial biogenesis, such as CD36 for fatty acids (FAs) transport into the cell, carnitine palmitoyl transferase 1 (CPT1) for FAs transport into the mitochondria, and the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1β (PGC1β). Inhibition of FAO prevents M2 from activation, whereas overexpression of PGC1β is sufficient to attenuate M1 activation in response to IFN-γ or LPS [58]. However, it is now apparent that FAO is not just anti-inflammatory as it also supports inflammasome activation. Intriguingly, the oxidation of palmitate via CPT1A promoted mitochondrial ROS production by fueling mitochondrial respiration, leading to the activation of NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) [59, 60]. The pharmacologic FAO inhibitor trimetazidine reduced progression of atherosclerotic plaques in a mouse model by reducing IL-1β and NLRP3 activation. Although FAO is largely dispensable for M2 macrophage activation and regulates memory and regulatory T cell formation [61], dietary FA supplementation directly affects the FA composition of atherosclerotic plaques. For instance, omega 3 FA supplementation leads to a significant increase in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in carotid plaques as well as decreased inflammation [62, 63]. FAO is known to support cellular longevity in other immune cells, but its role in macrophages remains unclear [64, 65].

Cholesterol and Lipid Affect Macrophage Phenotype in Atherosclerosis

Cholesterol is a component of cell membranes and a precursor to viarious biological molecules. Cholesterol metabolism influences the ability of macrophages to mount inflammatory responses in atherosclerosis. Moreover, cholesterol overload directly triggers the release of mitochondrial DNA and activates the AIM2 inflammasome in stimulated macrophages, leading to IL-1β production [66]. Additionally, the accumulation of cholesterol crystals in the artery during the early stages of atherosclerosis has been proposed to activate the inflammasome pathway in local macrophages, resulting in the generation of IL-1β. Furthermore, 25-hydroxycholesterol (25-HC), a metabolic intermediate in cholesterol metabolism, exacerbated inflammatory responses in lipid-laden macrophages by accelerating progression of atherosclerosis and promoting plaque instability. Moreover, 25-HC produced by activated lipid-loaded macrophages amplifies the inflammatory response by increasing TLR4 dependent signaling, enhancing apoptosis sensitivity, reducing efferocytotic capacity, and promoting paracrine effects in neighboring cells [67]. Additionally, cholesterol crystals could promote nuclear translocation of PKM2 to facilitate metabolic reprogramming and M1 macrophage polarization in primary human macrophages [68]. This suggests that accumulation of cholesterol crystals during the initial phases of atherosclerotic lesions may contribute to the modulation of macrophage phenotype and function (Fig. 1). In macrophages, cholesterol can be synthesized de novo or taken up in the form of LDL particles which transport cholesterol synthesized in the liver [69]. Cholesterol synthesis occurs in the cytosol, using acetyl-CoA as a substrate and is mediated by a series of enzymes targets by drugs designed to reduce blood cholesterol levels [70]. Excess cholesterol can be esterified, stored in lipid droplets, or removed from the cell through reverse cholesterol transport, a process in which surplus cholesterol is efflux to high-density lipoprotein (HDL) for transport back to the liver by ABC transporters on the cell surface [71]. Dysregulated cholesterol metabolism in arterial macrophages has long been recognized as pathogenic in atherosclerosis. Elevated levels of modified cholesterol, particularly oxLDL are important risk factors for the development of atherosclerosis. Macrophages uptake oxLDL within atherosclerotic plaques, leading to the formation of cholesterol-laden foam cells. The role of the cholesterol synthesis pathway in oxLDL-induced training remains to be established. OxLDL generates signals recognized by pattern recognition receptors (PRR) on macrophages and other immune cells [72]. Scavenger receptors such as, scavenger receptor A1 (SR-A1), CD36, and lectin-like oxLDL receptor-1 (LOX-1) mediate the uptake of oxLDL by macrophages, resulting in high cholesterol levels and the foam-like of macrophages. In vitro, SR-A1 and CD36 mediate over 75% of the degradation of modified LDL with combined deficiency of both receptors reducing but not totally preventing foam cell formation in mice, suggesting other mechanisms of LDL uptake in vivo. A recent study has showed that deficiency of nuclear factor of activated T cells 3 (NFATc3) in macrophages promotes foam cell formation by enhancing SR-A1 and CD36-meditated lipid uptake [73]. Foam cells contribute to plaque pathogenesis by producting numerous pro-inflammatory cytokines, chemokines and matrix metalloproteinases (MMP) which degrade extracellular matrix in plaques [74]. The accumulation of lipids and inflammatory cytokines induces endoplasmic reticulum (ER) stress through the unfolded protein response (UPR) to increase the sensitivity of arterial macrophages to apoptosis, contributing to plaque inflammation and destabilization. Accumulation of oxidized lipoproteins can also induce a M1 proinflammatory phenotype in human macrophages by inhibiting the transcription factor Kruppel­like factor 2. OxLDL promotes an inflammatory macrophage phenotype by activating a TLR4 mediated pathway in mice [75]. Cholesteryl esters induce M1 polarization by activating the TLR4 or NF­κB signaling pathways [76]. Regulation of cholesterol influx and efflux is crucial for the atherosclerosis progression. Liver X receptor (LXR) enhances the expression of cholesterol efflux transporters, controlling the cholesterol outflow. LXR activation exerts anti-inflammatory effects, partly due to the inhibition of TLR2, TLR4, and TLR9 signaling to their downstream NF-κB and MAPK effectors achieved by changes in membrane lipid composition mediated by ABCA1 [77, 78]. On the other side, HDL attenuates macrophage necroptosis by activating Akt signaling in macrophages in an SR-B1 and PDZK1-dependent manner, suppressing the formation of necrotic cores within atherosclerotic plaques [79].

Amino Acid Metabolism and Atherosclerosis

The metabolism of amino acid plays a critical role in the inflammation during atherogenesis. A recent study aimed to assess the impact of various amino acids on the macrophage in order to screen anti- or pro-atherogenic amino acids by a macrophage model system. Among the 20 amino acids, six specific amino acids including cysteine, histidine, methionine, lysine, arginine and tryptophan exhibited significantly cytotoxic effects on macrophages. The observed cytotoxicity was associated with increased generation of ROS and accumulation of cholesterol or triglycerides in macrophages. Histidine and tryptophan exhibit the most prominent efffects [80]. Homoarginine, a endogenous amino acid, has been identified as a strong biomarker with low circulating levels associated with increased risk of cardiovascular diseases [81]. In atherosclerosis, the metabolism of arginine, and its byproduct NO, is vitally important for the early stages of the disease [82]. Arginine can be used for synthesis of polyamines through the action of Arg1, which support macrophage proliferation and collagen production for IL-4 induced tissue repair [83]. Decreased bioavailability of NO and endothelial dysfunction are associated with risk factors for CAD [84, 85]. The oxidation of arginine produces NO and citrulline, which play crucial roles in maintaining the homeostasis of vascular tissue preventing abnormal proliferation of vascular smooth muscle cells, regulating leukocyte interaction with the vascular wall, presenting antigens, and maintaining vascular tone and growth. NO downstream of iNOS has been shown to suppress oxidative phosphorylation in inflammatory macrophages and the interaction of NO with ROS leads to the formation of even more reactive nitrogen species (RNS) such as peroxynitrit [86–89]. Amino acids leucine could activate mTORC1 in macrophages, raising questions about whether dietary proteins or amino acids exacerbate macrophage apoptosis induced by atherogenic lipids, a process involving mTORC1-dependent inhibition of mitophagy, accumulation and apoptosis of dysfunctional mitochondria [90]. Amino acids metabolism plays significant roles in inflammation and is important for the induction of IL-1 by macrophages in response to LPS stimulation as well as contributing NO generation by feeding into the arginine synthesis pathway [91]. Furthermore, glutamine deprivation has been shown to have profound functional consequences in M2 macrophages immunity, as glutamine flux into both the TCA cycle and hexosamine pathway promotes M2 macrophage polarization [92, 93].

Macrophage Roles in Progression and Regression of Plaques

Macrophages of distinct functional phenotypes play varying roles in atherosclerosis development. In mice, macrophages in early atherosclerotic lesions are mainly derived from recruited monocytes, while advanced plaques exhibit prominent macrophage proliferation influenced by signals from microenvironment. Consequently, differences in resident macrophage phenotypes can impact their local proliferation, altering the abundance of specific phenotype macrophages [93, 94]. In atherosclerosis, the pivotal feature is the ingestion and accumulation of lipoproteins by arterial macrophages, leading to the formation of foam cells [95]. The phenotype of macrophages in the carotid plaques of symptomatic patients during acute ischemic stroke has been compared with those from asymptomatic patients [93, 96]. The majority of the macrophages in the plaques of symptomatic patients exhibit M1 phenotype, whereas those from asymptomatic patients predominantly express markers of M2 polarization. Additionally, macrophages located in the lesion shoulder, considered one of the most unstable areas express M1 markers, whereas macrophages in the fibrous cap surrounding the necrotic core express both M1 and M2 markers [97–99]. In the adventitia, M2 macrophages are more abundant than M1 macrophages. Recent evidence suggests that macrophages exist on a continuum of activation and the M1/M2 classification system oversimplifies macrophage heterogeneity and functions [100, 101]. Furthermore, macrophage significantly impacts atherosclerotic lesion development and progression, contributing to cell death and plaque necrosis promoting lesion disruption and acute thrombosis lesioned arteries [102]. Under extensive oxidative stress, macrophage death occurs both in vivo and in vitro, accompanied by enhanced lipid accumulation. Leucine-enriched macrophage lipid accumulation could drive macrophage activation and atherogenesis. As the lesion progresses, the number of macrophages increases with symptomatic plaque containing more macrophages than asymptomatic plaques [95, 103]. Macrophages in shoulder regions of plaque fibrous cap mainly express M1 markers. Ruptured plaques express transcriptional markers of both M1 and M2 macrophages without preferential polarization and upregulate markers of both M1[e.g., CD68, HLA-DP/Q/R and macrophage receptor with collagenous structure (MARCO)] and M2 [(e.g. dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) and PPARγ] [99]. Additionally, markers of IPH such as CD163 and heme oxygenase-1 (HO-1) are highly upregulated in ruptured plaques, accumulating as plaques severity increases. Lesional foam cells exhibit markers are of both M1 (HLA-DP/Q/R and iNOS as well as dectin-1) and M2 phenotypes. Experimental data indicate that macrophage phenotype can switch to differential subtypes in response to the microenvironment. Suppressing M1 polarization and promoting enhanced M2 activation can accelerate plaque regression [104]. Overall, recent evidence supports the central role of macrophages in all stages of atherosclerosis and targeted lesional macrophage could be beneficial in protecting against atherosclerotic inflammation and lesion formation.

Therapeutic Targeting of Plaque Macrophages

Considering the pivotal role of macrophages in both the progression and regression of atherosclerotic lesions (Fig. 1), these cells present a crucial target for therapeutic intervention in ASCBD. Over the past few decades, the widespread implementation of lipid-lowering strategies, particularly statin therapy, has significantly revolutionized the management of cardiovascular disease, reducing the risk of acute cardiovascular events by 25–35%. As plaque macrophages plays a crucial role in atherogenesis, the primary mechanisms associated with macrophage activity, such as inflammation, oxidative stress, lipid metabolism and proliferation, are being explored as potential therapeutic targets [5]. Promoting cholesterol efflux is a key strategy to encourage atherosclerosis regression. LXR served as a transcription factor that triggers the expression of genes is involved in cholesterol transport and efflux and plays an essential role in impeding atherosclerosis progression and facilitating its regression [105, 106]. The nonspecific efflux molecule, cyclodextrin, promotes atherosclerosis regression through LXR-mediated reprogramming, leading to enhanced cholesterol efflux and exert anti-inflammatory effects. Yu and colleagues utilized biodegradable collagen type IV targeted polymeric nanoparticles to deliver the LXR agonist GW3965 to atherosclerotic lesions in LDLR –/– mice [107].

Furthermore, preclinical and clinical observations indicate that the reprogramming of plaque macrophages to an anti-inflammatory M2 phenotype can facilitate the regression and stabilization of atherosclerosis. Treatment of LDLR −/− mice with helminth-derived antigens derived form a eukaryotic parasitic worm has been shown to robustly stimulate anti-inflammatory immune responses, leading to the suppression of myeloid cell activation, i inflammation and reduced macrophages recruitment to lesions [108]. Combining this approach with lipid lowering therapies may represent a viable strategy for mitigating residual inflammatory cardiovascular disease risk in humans and expediting plaque regression. Nanomedicine provides an attractive strategy for locally targeting macrophage activity within atherosclerotic plaques [109]. A recently study showed that pterostilbene, T09 and simvastatin exhibited potent overall anti-atherogenic effects in macrophages, exerting beneficial impacts through multiple pathways simultaneously. Notably, monocyte recruitment to the arterial wall represents one of the earliest processes accelerating atherosclerosis progression [110]. In addition, siRNA-encapsulated polymeric nanoparticles are employed to inhibit monocyte recruitment to atherosclerotic lesions in ApoE–/– mice after myocardial infarction, concurrently inhibiting matrix-degrading protease activity in plaques by silencing endothelial cell adhesion molecules [111]. Furthermore, DPP-4 inhibitors can largely inhibit plaque formation in coronary arteries, resulting in a pronounced reduction in macrophages. Previous study utilized reconstituted HDL nanoparticles to deliver a small-molecule inhibitor targeting the tumor necrosis factor receptor-associated factor 6 interaction to circulating Ly6Chi monocytes, suppressing their pro-inflammatory response [112].

Apart from lipid metabolism and inflammation, the immune response plays a pivotal role in the pathogenesis of atherosclerosis. Modulation the immune response through the use of a vaccine containing antigens pertinent to atherogenesis holds promise for inducing a targeted immune response against these antigens while preserving overall host immunity. Intriguingly, administrating vaccines containing apoB100 peptides derived from oxLDL has shown therapeutic efficacy in mice atherosclerotic models by promoting the activation of regulatory T lymphocytes in the plaques. Furthermore, the emerging application of mRNA as a therapeutic tool has been utilized to modulate both innate and adaptive immunity responses through activating specific signaling pathways. Notably, the effective delivery of mRNA via nanoparticle-mediated strategies has revolutionized vaccine development, with mRNA vaccines being successfully employed to combat coronavirus disease 2019 (COVID-19) [113, 114]. Overall, we anticipate that technologies focusing on early targeting of macrophages to inhibit or diminish the inflammatory response hold potential for preventing the initiation and progression of atherosclerosis.

Conclusion and Perspectives

Macrophages are integral to the initiation and progression of atherosclerotic lesions, where phenotypes exhibit plasticity in response to changes in the microenvironment and specific stimuli. Macrophages undergo metabolic reprogramming in response to environmental cues such as hypoxia, apoptotic cells, and cytokines, leading to metabolic heterogeneity among plaque-resident macrophages. Metabolic changes of macrophages are likely to be dynamic due to the evolving microenvironment in plaque progression and disease management. Within the realm of fundamental macrophage biology, it is necessary to thoroughly comprehend how metabolic signatures of macrophages evolve in early atherogenesis and to elucidate the effects of specific metabolites in modulating distinct macrophage functions. More importantly, the exact relationship between immunometabolism in macrophages and atherosclerosis remains largely unclear. Further mechanistic in vivo investigations employing monocyte-macrophage targeted methodologies are warranted to furnish evidence of the causal roles of macrophage-derived metabolites in various stages of atherosclerosis lesion formation, encompassing early foam cell lesions, advanced plaques, and vulnerable plaques predisposed to rupture and subsequent acute myocardial infarction. There is increasing interest in exploiting the adaptability and polarization of macrophage, as well as their metabolic activities, to balance inflammatory responses and instate protective immune functions in atherosclerosis. A comprehensive comprehension of the specific metabolic reprogramming undergone by activated macrophages throughout the progression and regression of atherosclerosis is imperative for the discovery of innovative therapeutic approaches. Furthermore, the continued exploration of novel phenotypic and functional markers, coupled with the application of advanced expression profiling approaches as well as imaging technologies, is anticipated to refine and deepen the characterization and understanding of distinct roles played by various macrophage subtypes in atherosclerosis. The identification of biological triggers capable of affecting macrophage phenotypes holds promise for the development of novel therapeutic interventions for atherosclerosis and atherosclerotic cardiovascular diseases.

Key References

Wculek SK, Heras-Murillo I, Mastrangelo A, Mañanes D, Galán M, Miguel V, et al. Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis. Immunity. 2023;56(3):516-530.e9. (Identifies oxidative phosphorylation is critical for the maintenance of macrophages in tissues).

Kluck GEG, Qian AS, Sakarya EH, Quach H, Deng YD, Trigatti BL. Apolipoprotein A1 Protects Against Necrotic Core Development in Atherosclerotic Plaques: PDZK1-Dependent High-Density Lipoprotein Suppression of Necroptosis in Macrophages. Arterioscler Thromb Vasc Biol. 2023;43(1):45-63. (Identifies the new pathway to protect necroptosis of macrophages in atherosclerosis).

Edsfeldt A, Swart M, Singh P, Dib L. Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur Heart J. 2022;43(19):1864-1877. (Demonstrates macrophage phenotype may play important role in the rupture of atherosclerosis plaque).

Author contribution

J.W., WM.L., JC.Z., Q.W. and XY.W. wrote the main manuscript text and J.W., HB.L., ML.C, L.X. and KB.L. prepared Figs. 1–2, Z.Z. prepared Fig. 1. J.W., WM.L. and Z.Z. revised the manuscript. All authors reviewed the manuscript.

Funding

This work was supported by in part, by the National Natural Science Fund (NSFC, China, 81900382, 92168117, 82370432). Beijing Municipal Natural Science Foundation (7222072, 7222068).

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects.

Competing interests

The authors declare no competing interests.

Juan Wang, Qiang Wu and Xinyu Wang were co-first authors.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Williams JW Zaitsev K Kim KW Ivanov S Saunders BT Schrank PR Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression Nat Immunol 2020 21 10 1194 1204 10.1038/s41590-020-0768-4 32895539
Williams JW, Zaitsev K, Kim KW, Ivanov S, Saunders BT, Schrank PR, et al. Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression. Nat Immunol. 2020;21(10):1194–204.32895539 10.1038/s41590-020-0768-4
2. Oppi S Nusser-Stein S Blyszczuk P Wang X Jomard A Marzolla V Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature Eur Heart J 2020 41 9 995 1005 10.1093/eurheartj/ehz667 31529020
Oppi S, Nusser-Stein S, Blyszczuk P, Wang X, Jomard A, Marzolla V, et al. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature. Eur Heart J. 2020;41(9):995–1005.31529020 10.1093/eurheartj/ehz667
3. Leuschner F Nahrendorf M Novel functions of macrophages in the heart: insights into electrical conduction, stress, and diastolic dysfunction Eur Heart J 2020 41 9 989 994 10.1093/eurheartj/ehz159 30945736
Leuschner F, Nahrendorf M. Novel functions of macrophages in the heart: insights into electrical conduction, stress, and diastolic dysfunction. Eur Heart J. 2020;41(9):989–94.30945736 10.1093/eurheartj/ehz159
4. Evren E Ringqvist E Tripathi KP Sleiers N Rives IC Alisjahbana A Distinct developmental pathways from blood monocytes generate human lung macrophage diversity Immunity 2021 54 2 259 275.e7 10.1016/j.immuni.2020.12.003 33382972
Evren E, Ringqvist E, Tripathi KP, Sleiers N, Rives IC, Alisjahbana A, et al. Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. Immunity. 2021;54(2):259-275.e7.33382972 10.1016/j.immuni.2020.12.003
5. Galkina E Ley K Vascular adhesion molecules in atherosclerosis Arterioscler Thromb Vasc Biol 2007 27 11 2292 2301 10.1161/ATVBAHA.107.149179 17673705
Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292–301.17673705 10.1161/ATVBAHA.107.149179
6. Pourcet B Staels B Alternative macrophages in atherosclerosis: not always protective! J Clin Invest 2018 128 3 910 912 10.1172/JCI120123 29457787
Pourcet B, Staels B. Alternative macrophages in atherosclerosis: not always protective! J Clin Invest. 2018;128(3):910–2.29457787 10.1172/JCI120123
7. Moore KJ Koplev S Fisher EA Tabas I Björkegren JLM Doran AC Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (Part 2) J Am Coll Cardiol 2018 72 18 2181 2197 10.1016/j.jacc.2018.08.2147 30360827
Moore KJ, Koplev S, Fisher EA, Tabas I, Björkegren JLM, Doran AC, et al. Macrophage trafficking, inflammatory resolution, and genomics in atherosclerosis: JACC macrophage in CVD series (Part 2). J Am Coll Cardiol. 2018;72(18):2181–97.30360827 10.1016/j.jacc.2018.08.2147
8. Narasimhan PB Marcovecchio P Hamers AAJ Hedrick CC Nonclassical monocytes in health and disease Annu Rev Immunol 2019 37 439 456 10.1146/annurev-immunol-042617-053119 31026415
Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical monocytes in health and disease. Annu Rev Immunol. 2019;37:439–56.31026415 10.1146/annurev-immunol-042617-053119
9. Tang SCW Yiu WH Innate immunity in diabetic kidney disease Nat Rev Nephrol 2020 16 4 206 222 10.1038/s41581-019-0234-4 31942046
Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206–22.31942046 10.1038/s41581-019-0234-4
10. Wynn TA Vannella KM Macrophages in tissue repair, regeneration, and fibrosis Immunity 2016 44 3 450 462 10.1016/j.immuni.2016.02.015 26982353
Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44(3):450–62.26982353 10.1016/j.immuni.2016.02.015
11. Vannella KM Wynn TA Mechanisms of organ injury and repair by macrophages Annu Rev Physiol 2017 79 593 617 10.1146/annurev-physiol-022516-034356 27959618
Vannella KM, Wynn TA. Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol. 2017;79:593–617.27959618 10.1146/annurev-physiol-022516-034356
12. Mosser DM Edwards JP Exploring the full spectrum of macrophage activation Nat Rev Immunol 2008 8 12 958 969 10.1038/nri2448 19029990
Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–69.19029990 10.1038/nri2448
13. Xue J Schmidt SV Sander J Draffehn A Krebs W Quester I Transcriptome-based network analysis reveals a spectrum model of human macrophage activation Immunity 2014 40 2 274 288 10.1016/j.immuni.2014.01.006 24530056
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–88.24530056 10.1016/j.immuni.2014.01.006
14. Martinez FO Gordon S Locati M Mantovani A Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression J Immunol 2006 177 10 7303 7311 10.4049/jimmunol.177.10.7303 17082649
Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303–11.17082649 10.4049/jimmunol.177.10.7303
15. Ginhoux F Jung S Monocytes and macrophages: developmental pathways and tissue homeostasis Nat Rev Immunol 2014 14 6 392 404 10.1038/nri3671 24854589
Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392–404.24854589 10.1038/nri3671
16. Shapouri-Moghaddam A Mohammadian S Vazini H Taghadosi M Esmaeili SA Mardani F Macrophage plasticity, polarization, and function in health and disease J Cell Physiol 2018 233 9 6425 6440 10.1002/jcp.26429 29319160
Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–40.29319160 10.1002/jcp.26429
17. Barrett TJ Macrophages in atherosclerosis regression Arterioscler Thromb Vasc Biol 2020 40 1 20 33 10.1161/ATVBAHA.119.312802 31722535
Barrett TJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2020;40(1):20–33.31722535 10.1161/ATVBAHA.119.312802
18. Williams KJ Tabas I The response-to-retention hypothesis of early atherogenesis Arterioscler Thromb Vasc Biol 1995 15 5 551 561 10.1161/01.ATV.15.5.551 7749869
Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551–61.7749869 10.1161/01.ATV.15.5.551
19 Willenborg S Injarabian L Eming SA Role of macrophages in wound healing. role of macrophages in wound healing Cold Spring Harbor Perspect Biol 2022 14 12 041216
Willenborg S, Injarabian L, Eming SA. Role of macrophages in wound healing. role of macrophages in wound healing. Cold Spring Harbor Perspect Biol. 2022;14(12):041216.
20. Locati M Curtale G Mantovani A Diversity, mechanisms, and significance of macrophage plasticity Annu Rev Pathol 2020 15 123 147 10.1146/annurev-pathmechdis-012418-012718 31530089
Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47.31530089 10.1146/annurev-pathmechdis-012418-012718
21. Colin S Chinetti-Gbaguidi G Staels B Macrophage phenotypes in atherosclerosis Immunol Rev 2014 262 1 153 66 10.1111/imr.12218 25319333
Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev. 2014;262(1):153–66.25319333 10.1111/imr.12218
22. Abdelaziz MH Abdelwahab SF Alternatively activated macrophages; a double-edged sword in allergic asthma J Transl Med 2020 18 1 58 10.1186/s12967-020-02251-w 32024540
Abdelaziz MH, Abdelwahab SF. Alternatively activated macrophages; a double-edged sword in allergic asthma. J Transl Med. 2020;18(1):58.32024540 10.1186/s12967-020-02251-w
23. Tang L Zhang H Wang C Li H Zhang Q Bai J M2A and M2C macrophage subsets ameliorate inflammation and fibroproliferation in acute lung injury through interleukin 10 pathway Shock 2017 48 1 119 129 10.1097/SHK.0000000000000820 27941591
Tang L, Zhang H, Wang C, Li H, Zhang Q, Bai J. M2A and M2C macrophage subsets ameliorate inflammation and fibroproliferation in acute lung injury through interleukin 10 pathway. Shock. 2017;48(1):119–29.27941591 10.1097/SHK.0000000000000820
24 Sapudom J Karaman S Mohamed WKE Garcia-Sabaté A 3D in vitro M2 macrophage model to mimic modulation of tissue repair npj Regen Med 2021 6 1 83 10.1038/s41536-021-00193-5 34848722
Sapudom J, Karaman S, Mohamed WKE, Garcia-Sabaté A. 3D in vitro M2 macrophage model to mimic modulation of tissue repair. npj Regen Med. 2021;6(1):83.34848722 10.1038/s41536-021-00193-5
25. Chen MM Xiao X Lao XM Wei Y Liu RX Zeng QH Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization Cancer Discov 2016 6 10 1182 1195 10.1158/2159-8290.CD-16-0329 27531854
Chen MM, Xiao X, Lao XM, Wei Y, Liu RX, Zeng QH, et al. Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization. Cancer Discov. 2016;6(10):1182–95.27531854 10.1158/2159-8290.CD-16-0329
26. Rőszer T Understanding the mysterious M2 macrophage through activation markers and effector mechanisms Mediators Inflamm 2015 2015 816460 10.1155/2015/816460 26089604
Rőszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.26089604 10.1155/2015/816460
27. Liberale L Dallegri F Montecucco F Carbone F Pathophysiological relevance of macrophage subsets in atherogenesis Thromb Haemost 2017 117 1 7 18 10.1160/TH16-08-0593 27683760
Liberale L, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherogenesis. Thromb Haemost. 2017;117(1):7–18.27683760 10.1160/TH16-08-0593
28. Tariq M Zhang JQ Liang GK He QJ Ding L Yang B Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway Acta Pharmacol Sin 2017 38 11 1501 1511 10.1038/aps.2017.124 29022575
Tariq M, Zhang JQ, Liang GK, He QJ, Ding L, Yang B. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017;38(11):1501–11.29022575 10.1038/aps.2017.124
29. Zhang J Muri J Fitzgerald G Gorski T Gianni-Barrera R Masschelein E Endothelial Lactate Controls Muscle Regeneration from Ischemia by Inducing M2-like Macrophage Polarization Cell Metabo 2020 31 6 1136 1153.e7 10.1016/j.cmet.2020.05.004
Zhang J, Muri J, Fitzgerald G, Gorski T, Gianni-Barrera R, Masschelein E, et al. Endothelial Lactate Controls Muscle Regeneration from Ischemia by Inducing M2-like Macrophage Polarization. Cell Metabo. 2020;31(6):1136-1153.e7.10.1016/j.cmet.2020.05.004
30. Habib A Finn AV The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis Front Pharmacol 2014 27 5 195
Habib A, Finn AV. The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. Front Pharmacol. 2014;27(5):195.
31. Cochain C Zernecke A Macrophages and immune cells in atherosclerosis: recent advances and novel concepts Basic Res Cardiol 2015 110 4 34 10.1007/s00395-015-0491-8 25947006
Cochain C, Zernecke A. Macrophages and immune cells in atherosclerosis: recent advances and novel concepts. Basic Res Cardiol. 2015;110(4):34.25947006 10.1007/s00395-015-0491-8
32. Biswas SK Mantovani A Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat Immunol 2010 11 10 889 896 10.1038/ni.1937 20856220
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.20856220 10.1038/ni.1937
33. Chistiakov DA Bobryshev YV Nikiforov NG Elizova NV Sobenin IA Orekhov AN Macrophage phenotypic plasticity in atherosclerosis: the associated features and the peculiarities of the expression of inflammatory genes Int J Cardiol 2015 184 436 445 10.1016/j.ijcard.2015.03.055 25755062
Chistiakov DA, Bobryshev YV, Nikiforov NG, Elizova NV, Sobenin IA, Orekhov AN. Macrophage phenotypic plasticity in atherosclerosis: the associated features and the peculiarities of the expression of inflammatory genes. Int J Cardiol. 2015;184:436–45.25755062 10.1016/j.ijcard.2015.03.055
34. Mouton AJ Li X Hall ME Hall JE Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation Circ Res 2020 126 6 789 806 10.1161/CIRCRESAHA.119.312321 32163341
Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789–806.32163341 10.1161/CIRCRESAHA.119.312321
35. Van den Bossche J O'Neill LA Menon D macrophage immunometabolism: where are we (going)? Trends Immunol 2017 38 6 395 406 10.1016/j.it.2017.03.001 28396078
Van den Bossche J, O’Neill LA, Menon D. macrophage immunometabolism: where are we (going)? Trends Immunol. 2017;38(6):395–406.28396078 10.1016/j.it.2017.03.001
36. Liu PS Chen YT Li X Hsueh PC Tzeng SF Chen H CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions Nat Immunol 2023 24 3 452 462 10.1038/s41590-023-01430-3 36823405
Liu PS, Chen YT, Li X, Hsueh PC, Tzeng SF, Chen H, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol. 2023;24(3):452–62.36823405 10.1038/s41590-023-01430-3
37. Baidžajevas K Hadadi É Lee B Lum J Shihui F Sudbery I Macrophage polarisation associated with atherosclerosis differentially affects their capacity to handle lipids Atherosclerosis 2020 305 10 18 10.1016/j.atherosclerosis.2020.05.003 32592946
Baidžajevas K, Hadadi É, Lee B, Lum J, Shihui F, Sudbery I, et al. Macrophage polarisation associated with atherosclerosis differentially affects their capacity to handle lipids. Atherosclerosis. 2020;305:10–8.32592946 10.1016/j.atherosclerosis.2020.05.003
38. Renaudin F Orliaguet L Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages Ann Rheum Dis 2020 79 11 1506 1514 10.1136/annrheumdis-2020-217342 32699039
Renaudin F, Orliaguet L. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages. Ann Rheum Dis. 2020;79(11):1506–14.32699039 10.1136/annrheumdis-2020-217342
39. Haschemi A Kosma P Gille L Evans CR Burant CF Starkl P The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism Cell Metab 2012 15 6 813 826 10.1016/j.cmet.2012.04.023 22682222
Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 2012;15(6):813–26.22682222 10.1016/j.cmet.2012.04.023
40. Yu W Wang Z Zhang K Chi Z Xu T Jiang D One-carbon metabolism supports S-Adenosylmethionine and histone methylation to drive inflammatory macrophages Mol Cell 2019 75 1147 1160.e1145 10.1016/j.molcel.2019.06.039 31420217
Yu W, Wang Z, Zhang K, Chi Z, Xu T, Jiang D, et al. One-carbon metabolism supports S-Adenosylmethionine and histone methylation to drive inflammatory macrophages. Mol Cell. 2019;75:1147-1160.e1145.31420217 10.1016/j.molcel.2019.06.039
41. Wu SB Wei YH AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases Biochim Biophys Acta 2012 1822 2 233 247 10.1016/j.bbadis.2011.09.014 22001850
Wu SB, Wei YH. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim Biophys Acta. 2012;1822(2):233–47.22001850 10.1016/j.bbadis.2011.09.014
42. Shirai T Nazarewicz RR Wallis BB Yanes RE Watanabe R Hilhorst M The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease J Exp Med 2016 213 3 337 354 10.1084/jem.20150900 26926996
Shirai T, Nazarewicz RR, Wallis BB, Yanes RE, Watanabe R, Hilhorst M, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med. 2016;213(3):337–54.26926996 10.1084/jem.20150900
43. Semba H Takeda N Isagawa T Sugiura Y Honda K Wake M HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity Nat Commun 2016 7 11635 10.1038/ncomms11635 27189088
Semba H, Takeda N, Isagawa T, Sugiura Y, Honda K, Wake M, et al. HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity. Nat Commun. 2016;7:11635.27189088 10.1038/ncomms11635
44. Ginouvès A Ilc K Macías N Pouysségur J Berra E PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis Proc Natl Acad Sci U S A 2008 105 12 4745 4750 10.1073/pnas.0705680105 18347341
Ginouvès A, Ilc K, Macías N, Pouysségur J, Berra E. PHDs overactivation during chronic hypoxia “desensitizes” HIFalpha and protects cells from necrosis. Proc Natl Acad Sci U S A. 2008;105(12):4745–50.18347341 10.1073/pnas.0705680105
45. Jain IH Calvo SE Markhard AL Skinner OS To TL Ast T Genetic screen for cell fitness in high or low oxygen highlights mitochondrial and lipid metabolism Cell 2020 181 3 716 727.e11 10.1016/j.cell.2020.03.029 32259488
Jain IH, Calvo SE, Markhard AL, Skinner OS, To TL, Ast T, et al. Genetic screen for cell fitness in high or low oxygen highlights mitochondrial and lipid metabolism. Cell. 2020;181(3):716-727.e11.32259488 10.1016/j.cell.2020.03.029
46. Covarrubias AJ Aksoylar HI Horng T Control of macrophage metabolism and activation by mTOR and Akt signaling Semin Immunol 2015 27 4 286 296 10.1016/j.smim.2015.08.001 26360589
Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin Immunol. 2015;27(4):286–96.26360589 10.1016/j.smim.2015.08.001
47. Kumamoto Y Camporez JPG Jurczak MJ Shanabrough M Horvath T Shulman GI CD301b(+) Mononuclear Phagocytes Maintain Positive Energy Balance through Secretion of Resistin-like Molecule Alpha Immunity 2016 45 3 583 596 10.1016/j.immuni.2016.08.002 27566941
Kumamoto Y, Camporez JPG, Jurczak MJ, Shanabrough M, Horvath T, Shulman GI, et al. CD301b(+) Mononuclear Phagocytes Maintain Positive Energy Balance through Secretion of Resistin-like Molecule Alpha. Immunity. 2016;45(3):583–96.27566941 10.1016/j.immuni.2016.08.002
48. Puleston DJ Buck MD Klein Geltink RI Kyle RL Caputa G O'Sullivan D Polyamines and eIF5A hypusination modulate mitochondrial respiration and macrophage activation Cell Metab 2019 30 2 352 363.e8 10.1016/j.cmet.2019.05.003 31130465
Puleston DJ, Buck MD, Klein Geltink RI, Kyle RL, Caputa G, O’Sullivan D, et al. Polyamines and eIF5A hypusination modulate mitochondrial respiration and macrophage activation. Cell Metab. 2019;30(2):352-363.e8.31130465 10.1016/j.cmet.2019.05.003
49. Wang F Zhang S Vuckovic I Jeon R Lerman A Folmes CD Glycolytic stimulation is not a requirement for M2 macrophage differentiation Cell Metab 2018 28 3 463 475.e4 10.1016/j.cmet.2018.08.012 30184486
Wang F, Zhang S, Vuckovic I, Jeon R, Lerman A, Folmes CD, et al. Glycolytic stimulation is not a requirement for M2 macrophage differentiation. Cell Metab. 2018;28(3):463-475.e4.30184486 10.1016/j.cmet.2018.08.012
50. Wculek SK Heras-Murillo I Mastrangelo A Mañanes D Galán M Miguel V Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis Immunity 2023 56 3 516 530.e9 10.1016/j.immuni.2023.01.011 36738738
Wculek SK, Heras-Murillo I, Mastrangelo A, Mañanes D, Galán M, Miguel V, et al. Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis. Immunity. 2023;56(3):516-530.e9 Identifies oxidative phosphorylation is critical for the maintenance of macrophages in tissues.36738738 10.1016/j.immuni.2023.01.011
51. Blagih J Jones RG Polarizing macrophages through reprogramming of glucose metabolism Cell Metab 2012 15 6 793 795 10.1016/j.cmet.2012.05.008 22682218
Blagih J, Jones RG. Polarizing macrophages through reprogramming of glucose metabolism. Cell Metab. 2012;15(6):793–5.22682218 10.1016/j.cmet.2012.05.008
52. Wang YT Trzeciak AJ Rojas WS Saavedra P Chen YT Chirayil R Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments Cell Metab 2023 35 2 316 331.e6 10.1016/j.cmet.2022.12.005 36584675
Wang YT, Trzeciak AJ, Rojas WS, Saavedra P, Chen YT, Chirayil R, et al. Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. Cell Metab. 2023;35(2):316-331.e6.36584675 10.1016/j.cmet.2022.12.005
53. Cho H Kwon HY Sharma A Visualizing inflammation with an M1 macrophage selective probe via GLUT1 as the gating target Nat Commun 2022 13 1 5974 10.1038/s41467-022-33526-z 36216803
Cho H, Kwon HY, Sharma A. Visualizing inflammation with an M1 macrophage selective probe via GLUT1 as the gating target. Nat Commun. 2022;13(1):5974.36216803 10.1038/s41467-022-33526-z
54. Kim SR Lee SG SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease Nat Commun 2020 11 1 2127 10.1038/s41467-020-15983-6 32358544
Kim SR, Lee SG. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.32358544 10.1038/s41467-020-15983-6
55. Heerspink HJ Perkins BA Fitchett DH Husain M Cherney DZ Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications Circulation 2016 134 10 752 772 10.1161/CIRCULATIONAHA.116.021887 27470878
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72.27470878 10.1161/CIRCULATIONAHA.116.021887
56. Groh L Keating ST Joosten LAB Netea MG Riksen NP Monocyte and macrophage immunometabolism in atherosclerosis Seminars Immunopathol Semin Immunopathol 2018 40 2 203 214 10.1007/s00281-017-0656-7
Groh L, Keating ST, Joosten LAB, Netea MG, Riksen NP. Monocyte and macrophage immunometabolism in atherosclerosis. Seminars Immunopathol Semin Immunopathol. 2018;40(2):203–14.10.1007/s00281-017-0656-7
57. Cader MZ Boroviak K Zhang Q Assadi G Kempster SL Sewell GW C13orf31 (FAMIN) is a central regulator of immunometabolic function Nat Immunol 2016 17 9 1046 1056 10.1038/ni.3532 27478939
Cader MZ, Boroviak K, Zhang Q, Assadi G, Kempster SL, Sewell GW, et al. C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol. 2016;17(9):1046–56.27478939 10.1038/ni.3532
58. Huang SC Everts B Ivanova Y O'Sullivan D Nascimento M Smith AM Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages Nat Immunol 2014 15 9 846 855 10.1038/ni.2956 25086775
Huang SC, Everts B, Ivanova Y, O’Sullivan D, Nascimento M, Smith AM, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014;15(9):846–55.25086775 10.1038/ni.2956
59. Moon JS Nakahira K Chung KP DeNicola GM Koo MJ Pabón MA NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages Nat Med 2016 22 9 1002 1012 10.1038/nm.4153 27455510
Moon JS, Nakahira K, Chung KP, DeNicola GM, Koo MJ, Pabón MA, et al. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med. 2016;22(9):1002–12.27455510 10.1038/nm.4153
60. Hall CJ Boyle RH Astin JW Flores MV Oehlers SH Sanderson LE Immunoresponsive gene 1 augments bactericidal activity of macrophage-lineage cells by regulating β-oxidation-dependent mitochondrial ROS production Cell Metab 2013 18 2 265 278 10.1016/j.cmet.2013.06.018 23931757
Hall CJ, Boyle RH, Astin JW, Flores MV, Oehlers SH, Sanderson LE, et al. Immunoresponsive gene 1 augments bactericidal activity of macrophage-lineage cells by regulating β-oxidation-dependent mitochondrial ROS production. Cell Metab. 2013;18(2):265–78.23931757 10.1016/j.cmet.2013.06.018
61. Van den Bossche J van der Windt GJW Fatty Acid Oxidation in macrophages and T Cells: time for reassessment? Cell Metab 2018 28 4 538 540 10.1016/j.cmet.2018.09.018 30282046
Van den Bossche J, van der Windt GJW. Fatty Acid Oxidation in macrophages and T Cells: time for reassessment? Cell Metab. 2018;28(4):538–40.30282046 10.1016/j.cmet.2018.09.018
62. Thies F Garry JM Yaqoob P Rerkasem K Williams J Shearman CP Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial Lancet 2003 361 9356 477 485 10.1016/S0140-6736(03)12468-3 12583947
Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361(9356):477–85.12583947 10.1016/S0140-6736(03)12468-3
63. Bhatt DL Steg PG Miller M Brinton EA Jacobson TA Ketchum SB Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia N Engl J Med 2019 380 1 11 22 10.1056/NEJMoa1812792 30415628
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.30415628 10.1056/NEJMoa1812792
64. Pearce EL Metabolism in T cell activation and differentiation Curr Opin Immunol 2010 22 3 314 320 10.1016/j.coi.2010.01.018 20189791
Pearce EL. Metabolism in T cell activation and differentiation. Curr Opin Immunol. 2010;22(3):314–20.20189791 10.1016/j.coi.2010.01.018
65. van der Windt GJ Everts B Chang CH Curtis JD Freitas TC Amiel E Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development Immunity 2012 36 1 68 78 10.1016/j.immuni.2011.12.007 22206904
van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012;36(1):68–78.22206904 10.1016/j.immuni.2011.12.007
66 Dang EV McDonald JG Russell DW Cyster JG Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation Cell 2017 171 5 1057 1071.e11 10.1016/j.cell.2017.09.029 29033131
Dang EV, McDonald JG, Russell DW, Cyster JG. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation. Cell. 2017;171(5):1057-1071.e11.29033131 10.1016/j.cell.2017.09.029
67. Canfrán-Duque A Rotllan N Zhang X Andrés-Blasco I Macrophage-derived 25-hydroxycholesterol promotes vascular inflammation, atherogenesis, and lesion remodeling Circulation 2023 147 5 388 408 10.1161/CIRCULATIONAHA.122.059062 36416142
Canfrán-Duque A, Rotllan N, Zhang X, Andrés-Blasco I. Macrophage-derived 25-hydroxycholesterol promotes vascular inflammation, atherogenesis, and lesion remodeling. Circulation. 2023;147(5):388–408.36416142 10.1161/CIRCULATIONAHA.122.059062
68. O'Rourke SA Neto NGB Devilly E Shanley LC Fitzgerald HK Monaghan MG Cholesterol crystals drive metabolic reprogramming and M1 macrophage polarisation in primary human macrophages Atherosclerosis 2022 352 35 45 10.1016/j.atherosclerosis.2022.05.015 35667162
O’Rourke SA, Neto NGB, Devilly E, Shanley LC, Fitzgerald HK, Monaghan MG, et al. Cholesterol crystals drive metabolic reprogramming and M1 macrophage polarisation in primary human macrophages. Atherosclerosis. 2022;352:35–45.35667162 10.1016/j.atherosclerosis.2022.05.015
69. Nurmohamed NS Ditmarsch M Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res 2022 118 14 2919 2931 10.1093/cvr/cvab350 34849601
Nurmohamed NS, Ditmarsch M. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919–31.34849601 10.1093/cvr/cvab350
70. Goedeke L Fernández-Hernando C Regulation of cholesterol homeostasis Cell Mol Life Sci 2012 69 6 915 930 10.1007/s00018-011-0857-5 22009455
Goedeke L, Fernández-Hernando C. Regulation of cholesterol homeostasis. Cell Mol Life Sci. 2012;69(6):915–30.22009455 10.1007/s00018-011-0857-5
71. Tall AR Yvan-Charvet L Terasaka N Pagler T Wang N HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab 2008 7 5 365 375 10.1016/j.cmet.2008.03.001 18460328
Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365–75.18460328 10.1016/j.cmet.2008.03.001
72. Libby P Aikawa M Schönbeck U Cholesterol and atherosclerosis Biochim Biophys Acta 2000 1529 1–3 299 309 10.1016/S1388-1981(00)00161-X 11111097
Libby P, Aikawa M, Schönbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529(1–3):299–309.11111097 10.1016/S1388-1981(00)00161-X
73 Liu X Guo JW Lin XC Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms Eur Heart J 2021 42 4847 4861 10.1093/eurheartj/ehab660 34570211
Liu X, Guo JW, Lin XC. Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms. Eur Heart J. 2021;42:4847–61.34570211 10.1093/eurheartj/ehab660
74. Di Gregoli K Jenkins N Salter R White S Newby AC Johnson JL MicroRNA-24 regulates macrophage behavior and retards atherosclerosis Arterioscler Thromb Vasc Biol 2014 34 9 1990 2000 10.1161/ATVBAHA.114.304088 24990232
Di Gregoli K, Jenkins N, Salter R, White S, Newby AC, Johnson JL. MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(9):1990–2000.24990232 10.1161/ATVBAHA.114.304088
75. Xu Y Kong X Zhou H Zhang X Liu J Yan J oxLDL/β2GPI/anti-β2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway Thromb Res 2014 134 2 384 392 10.1016/j.thromres.2014.05.017 24882274
Xu Y, Kong X, Zhou H, Zhang X, Liu J, Yan J, et al. oxLDL/β2GPI/anti-β2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway. Thromb Res. 2014;134(2):384–92.24882274 10.1016/j.thromres.2014.05.017
76. Ackerman D Tumanov S Qiu B Michalopoulou E Spata M Azzam A Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation Cell Rep 2018 24 10 2596 2605.e5 10.1016/j.celrep.2018.08.015 30184495
Ackerman D, Tumanov S, Qiu B, Michalopoulou E, Spata M, Azzam A, et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 2018;24(10):2596-2605.e5.30184495 10.1016/j.celrep.2018.08.015
77. Kong XN Yan HX Chen L Dong LW Yang W Liu Q LPS-induced down-regulation of signal regulatory protein alpha contributes to innate immune activation in macrophages J Exp Med 2007 204 11 2719 2731 10.1084/jem.20062611 17954568
Kong XN, Yan HX, Chen L, Dong LW, Yang W, Liu Q, et al. LPS-induced down-regulation of signal regulatory protein alpha contributes to innate immune activation in macrophages. J Exp Med. 2007;204(11):2719–31.17954568 10.1084/jem.20062611
78. Tall AR Yvan-Charvet L Cholesterol, inflammation and innate immunity Nat Rev Immunol 2015 15 2 104 116 10.1038/nri3793 25614320
Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–16.25614320 10.1038/nri3793
79 Kluck GEG Qian AS Sakarya EH Quach H Deng YD Trigatti BL Apolipoprotein A1 protects against necrotic core development in atherosclerotic plaques: PDZK1-dependent high-density lipoprotein suppression of necroptosis in macrophages Arterioscler Thromb Vasc Bio 2023 43 1 45 63 10.1161/ATVBAHA.122.318062 36353992
Kluck GEG, Qian AS, Sakarya EH, Quach H, Deng YD, Trigatti BL. Apolipoprotein A1 protects against necrotic core development in atherosclerotic plaques: PDZK1-dependent high-density lipoprotein suppression of necroptosis in macrophages. Arterioscler Thromb Vasc Bio. 2023;43(1):45–63 Identifies the new pathway to protect necroptosis of macrophages in atherosclerosis.36353992 10.1161/ATVBAHA.122.318062
80. Rom O Grajeda-Iglesias C Najjar M Abu-Saleh N Volkova N Dar DE Atherogenicity of amino acids in the lipid-laden macrophage model system in vitro and in atherosclerotic mice: a key role for triglyceride metabolism J Nutr Biochem 2017 45 24 38 10.1016/j.jnutbio.2017.02.023 28431321
Rom O, Grajeda-Iglesias C, Najjar M, Abu-Saleh N, Volkova N, Dar DE, et al. Atherogenicity of amino acids in the lipid-laden macrophage model system in vitro and in atherosclerotic mice: a key role for triglyceride metabolism. J Nutr Biochem. 2017;45:24–38.28431321 10.1016/j.jnutbio.2017.02.023
81. Nitz K Lacy M Bianchini M Wichapong K The amino acid homoarginine inhibits atherogenesis by modulating T-Cell function Circ Res 2022 131 8 701 712 10.1161/CIRCRESAHA.122.321094 36102188
Nitz K, Lacy M, Bianchini M, Wichapong K. The amino acid homoarginine inhibits atherogenesis by modulating T-Cell function. Circ Res. 2022;131(8):701–12.36102188 10.1161/CIRCRESAHA.122.321094
82. Nitz K Lacy M Atzler D Amino acids and their metabolism in atherosclerosis Arterioscler Thromb Vasc Biol 2019 39 3 319 330 10.1161/ATVBAHA.118.311572 30650999
Nitz K, Lacy M, Atzler D. Amino acids and their metabolism in atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(3):319–30.30650999 10.1161/ATVBAHA.118.311572
83. Boutens L Hooiveld GJ Dhingra S Cramer RA Netea MG Stienstra R Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses Diabetologia 2018 61 4 942 953 10.1007/s00125-017-4526-6 29333574
Boutens L, Hooiveld GJ, Dhingra S, Cramer RA, Netea MG, Stienstra R. Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses. Diabetologia. 2018;61(4):942–53.29333574 10.1007/s00125-017-4526-6
84. Gutiérrez E Flammer AJ Lerman LO Elízaga J Lerman A Fernández-Avilés F Endothelial dysfunction over the course of coronary artery disease Eur Heart J 2013 34 41 3175 3181 10.1093/eurheartj/eht351 24014385
Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, Lerman A, Fernández-Avilés F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175–81.24014385 10.1093/eurheartj/eht351
85. Kratzer A Giral H Landmesser U High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease Cardiovasc Res 2014 103 3 350 361 10.1093/cvr/cvu139 24935432
Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res. 2014;103(3):350–61.24935432 10.1093/cvr/cvu139
86. Van den Bossche J Baardman J Otto NA van der Velden S Neele AE van den Berg SM Mitochondrial dysfunction prevents repolarization of inflammatory macrophages Cell Rep 2016 17 3 684 696 10.1016/j.celrep.2016.09.008 27732846
Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 2016;17(3):684–96.27732846 10.1016/j.celrep.2016.09.008
87. Everts B Amiel E van der Windt GJ Freitas TC Chott R Yarasheski KE Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells Blood 2012 120 7 1422 1431 10.1182/blood-2012-03-419747 22786879
Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood. 2012;120(7):1422–31.22786879 10.1182/blood-2012-03-419747
88. Tabas I Bornfeldt KE Intracellular and intercellular aspects of macrophage immunometabolism in atherosclerosis Circ Res 2020 126 9 1209 1227 10.1161/CIRCRESAHA.119.315939 32324504
Tabas I, Bornfeldt KE. Intracellular and intercellular aspects of macrophage immunometabolism in atherosclerosis. Circ Res. 2020;126(9):1209–27.32324504 10.1161/CIRCRESAHA.119.315939
89. Alef MJ Vallabhaneni R Carchman E Morris SM Jr Shiva S Wang Y Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats J Clin Invest 2011 121 4 1646 1656 10.1172/JCI44079 21436585
Alef MJ, Vallabhaneni R, Carchman E, Morris SM Jr, Shiva S, Wang Y, et al. Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats. J Clin Invest. 2011;121(4):1646–56.21436585 10.1172/JCI44079
90. Zhang X Sergin I Evans TD Jeong SJ Rodriguez-Velez A Kapoor D High-protein diets increase cardiovascular risk by activating macrophage mTOR to suppress mitophagy Nat Metab 2020 2 1 110 125 10.1038/s42255-019-0162-4 32128508
Zhang X, Sergin I, Evans TD, Jeong SJ, Rodriguez-Velez A, Kapoor D, et al. High-protein diets increase cardiovascular risk by activating macrophage mTOR to suppress mitophagy. Nat Metab. 2020;2(1):110–25.32128508 10.1038/s42255-019-0162-4
91 Wallace C Keast D Glutamine and macrophage function Metabolism: Clin Exp 1992 41 9 1016 1020 10.1016/0026-0495(92)90130-3
Wallace C, Keast D. Glutamine and macrophage function. Metabolism: Clin Exp. 1992;41(9):1016–20.10.1016/0026-0495(92)90130-3
92. Jha AK Huang SC Sergushichev A Lampropoulou V Ivanova Y Loginicheva E Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization Immunity 2015 42 3 419 430 10.1016/j.immuni.2015.02.005 25786174
Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42(3):419–30.25786174 10.1016/j.immuni.2015.02.005
93. Jenkins SJ Ruckerl D Cook PC Jones LH Finkelman FD van Rooijen N Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation Science 2011 332 1284 1288 10.1126/science.1204351 21566158
Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332:1284–8.21566158 10.1126/science.1204351
94. Jenkins SJ Ruckerl D Thomas GD Hewitson JP Duncan S Brombacher F IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1 J Exp Med 2013 210 11 2477 2491 10.1084/jem.20121999 24101381
Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, et al. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013;210(11):2477–91.24101381 10.1084/jem.20121999
95. Wang J Liu H Sun J Xue H Xie L Yu S Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation Stroke 2014 45 6 1842 1845 10.1161/STROKEAHA.114.005147 24788973
Wang J, Liu H, Sun J, Xue H, Xie L, Yu S, et al. Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation. Stroke. 2014;45(6):1842–5.24788973 10.1161/STROKEAHA.114.005147
96. van Dam-Nolen DHK Truijman MTB van der Kolk AG Liem MI Schreuder FHBM Boersma E Carotid plaque characteristics predict recurrent ischemic stroke and TIA: the parisk (Plaque At RISK) Study JACC Cardiovasc Imaging 2022 15 10 1715 1726 10.1016/j.jcmg.2022.04.003 36202450
van Dam-Nolen DHK, Truijman MTB, van der Kolk AG, Liem MI, Schreuder FHBM, Boersma E, et al. Carotid plaque characteristics predict recurrent ischemic stroke and TIA: the parisk (Plaque At RISK) Study. JACC Cardiovasc Imaging. 2022;15(10):1715–26.36202450 10.1016/j.jcmg.2022.04.003
97. Barlis P Serruys PW Devries A Regar E Optical coherence tomography assessment of vulnerable plaque rupture: predilection for the plaque 'shoulder' Eur Heart J 2008 29 16 2023 10.1093/eurheartj/ehn085 18337236
Barlis P, Serruys PW, Devries A, Regar E. Optical coherence tomography assessment of vulnerable plaque rupture: predilection for the plaque “shoulder.” Eur Heart J. 2008;29(16):2023.18337236 10.1093/eurheartj/ehn085
98. Edsfeldt A Swart M Singh P Dib L Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques Eur Heart J 2022 43 19 1864 1877 10.1093/eurheartj/ehab920 35567557
Edsfeldt A, Swart M, Singh P, Dib L. Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur Heart J. 2022;43(19):1864–77 Demonstrates macrophage phenotype may play important role in the rupture of atherosclerosis plaque.35567557 10.1093/eurheartj/ehab920
99. Lee CG Homer RJ Zhu Z Lanone S Wang X Koteliansky V Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta J Exp Med 2001 194 6 809 821 10.1084/jem.194.6.809 11560996
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta. J Exp Med. 2001;194(6):809–21.11560996 10.1084/jem.194.6.809
100. Stöger JL Gijbels MJ van der Velden S Manca M van der Loos CM Biessen EA Distribution of macrophage polarization markers in human atherosclerosis Atherosclerosis 2012 225 2 461 468 10.1016/j.atherosclerosis.2012.09.013 23078881
Stöger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461–8.23078881 10.1016/j.atherosclerosis.2012.09.013
101. Williams JW Giannarelli C Rahman A Randolph GJ Kovacic JC Macrophage biology, classification, and phenotype in cardiovascular disease: JACC macrophage in CVD Series (Part 1) J Am Coll Cardiol 2018 72 18 2166 2180 10.1016/j.jacc.2018.08.2148 30360826
Williams JW, Giannarelli C, Rahman A, Randolph GJ, Kovacic JC. Macrophage biology, classification, and phenotype in cardiovascular disease: JACC macrophage in CVD Series (Part 1). J Am Coll Cardiol. 2018;72(18):2166–80.30360826 10.1016/j.jacc.2018.08.2148
102. Robinson N Ganesan R Hegedűs C Kovács K Kufer TA Virág L Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos Redox Biol 2019 26 101239 10.1016/j.redox.2019.101239 31212216
Robinson N, Ganesan R, Hegedűs C, Kovács K, Kufer TA, Virág L. Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos. Redox Biol. 2019;26:101239.31212216 10.1016/j.redox.2019.101239
103. Golledge J Greenhalgh RM Davies AH The symptomatic carotid plaque Stroke 2000 31 3 774 781 10.1161/01.STR.31.3.774 10700518
Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. Stroke. 2000;31(3):774–81.10700518 10.1161/01.STR.31.3.774
104. Liu Y Wang X Pang J Zhang H Luo J Qian X attenuation of atherosclerosis by protocatechuic acid via inhibition of M1 and promotion of M2 macrophage polarization J Agric Food Chem 2019 67 3 807 818 10.1021/acs.jafc.8b05719 30592218
Liu Y, Wang X, Pang J, Zhang H, Luo J, Qian X, et al. attenuation of atherosclerosis by protocatechuic acid via inhibition of M1 and promotion of M2 macrophage polarization. J Agric Food Chem. 2019;67(3):807–18.30592218 10.1021/acs.jafc.8b05719
105. Shrestha E Hussein MA Savas JN Ouimet M Barrett TJ Leone S Poly (ADP-ribose) polymerase 1 represses liver X receptor-mediated ABCA1 expression and cholesterol efflux in macrophages J Biol Chem 2016 291 21 11172 11184 10.1074/jbc.M116.726729 27026705
Shrestha E, Hussein MA, Savas JN, Ouimet M, Barrett TJ, Leone S, et al. Poly (ADP-ribose) polymerase 1 represses liver X receptor-mediated ABCA1 expression and cholesterol efflux in macrophages. J Biol Chem. 2016;291(21):11172–84.27026705 10.1074/jbc.M116.726729
106. Lee SD Tontonoz P Liver X receptors at the intersection of lipid metabolism and atherogenesis Atherosclerosis 2015 242 1 29 36 10.1016/j.atherosclerosis.2015.06.042 26164157
Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis. 2015;242(1):29–36.26164157 10.1016/j.atherosclerosis.2015.06.042
107. Yu M, Amengual J, Menon A, Kamaly N, Zhou F, Xu X, et al. Targeted nanotherapeutics encapsulating liver X receptor agonist GW3965 enhance antiatherogenic effects without adverse effects on hepatic lipid metabolism in Ldlr-/- Mice. Adv Healthc Mater. 2017;6(20). 10.1002/adhm.201700313
108. Wolfs IM Stöger JL Goossens P Pöttgens C Gijbels MJ Wijnands E Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis FASEB J 2014 28 1 288 299 10.1096/fj.13-235911 24043262
Wolfs IM, Stöger JL, Goossens P, Pöttgens C, Gijbels MJ, Wijnands E, et al. Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis. FASEB J. 2014;28(1):288–99.24043262 10.1096/fj.13-235911
109. Chen W Schilperoort M Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis Nat Rev Cardiol 2022 19 4 228 249 10.1038/s41569-021-00629-x 34759324
Chen W, Schilperoort M. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat Rev Cardiol. 2022;19(4):228–49.34759324 10.1038/s41569-021-00629-x
110. Alaarg A Zheng KH van der Valk FM da Silva AE Versloot M van Ufford LC Schulte DM Storm G Metselaar JM Stroes ES Hamers AA Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques Vascul Pharmacol 2016 82 51 59 10.1016/j.vph.2016.04.006 27189780
Alaarg A, Zheng KH, van der Valk FM, da Silva AE, Versloot M, van Ufford LC, Schulte DM, Storm G, Metselaar JM, Stroes ES, Hamers AA. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Vascul Pharmacol. 2016;82:51–9.27189780 10.1016/j.vph.2016.04.006
111. Sager HB Dutta P Dahlman JE Hulsmans M Courties G Sun Y Heidt T Vinegoni C Borodovsky A Fitzgerald K Wojtkiewicz GR Iwamoto Y Tricot B Khan OF Kauffman KJ Xing Y Shaw TE Libby P Langer R Weissleder R Swirski FK Anderson DG Nahrendorf M RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction Sci Transl Med. 2016 8 342 342ra80 10.1126/scitranslmed.aaf1435 27280687
Sager HB, Dutta P, Dahlman JE, Hulsmans M, Courties G, Sun Y, Heidt T, Vinegoni C, Borodovsky A, Fitzgerald K, Wojtkiewicz GR, Iwamoto Y, Tricot B, Khan OF, Kauffman KJ, Xing Y, Shaw TE, Libby P, Langer R, Weissleder R, Swirski FK, Anderson DG, Nahrendorf M. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med. 2016;8(342):342ra80.27280687 10.1126/scitranslmed.aaf1435
112. Braza MS van Leent MMT Lameijer M Sanchez-Gaytan BL Arts RJW Pérez-Medina C Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance Immunity 2018 49 5 819 828.e6 10.1016/j.immuni.2018.09.008 30413362
Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. Immunity. 2018;49(5):819-828.e6.30413362 10.1016/j.immuni.2018.09.008
113. Powles T Rosenberg JE Sonpavde GP Loriot Y Durán I Lee JL Enfortumab vedotin in previously treated advanced urothelial carcinoma N Engl J Med 2021 384 12 1125 1135 10.1056/NEJMoa2035807 33577729
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35.33577729 10.1056/NEJMoa2035807
114. Polack FP Thomas SJ Kitchin N Absalon J Gurtman A Lockhart S Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med 2020 383 27 2603 2615 10.1056/NEJMoa2034577 33301246
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.33301246 10.1056/NEJMoa2034577
